Royal Marsden teams up with Guardant Health
The Royal Marsden NHS Foundation Trust has partnered with Guardant Health, a US-based precision oncology company, to provide better patient access to personalised cancer treatment.
The partnership will see The Royal Marsden, which has hospitals in Chelsea and Sutton, establish its first in-house liquid biopsy testing service in the UK, using Guardant Health’s proprietary digital sequencing platform.
The service will enable clinicians at The Royal Marsden to personalise treatments more accurately for patients with late-stage cancer and advance cancer research.
Hill Dickinson law firm advised The Royal Marsden.
Professor https://healthinvestor.co.uk/wp-content/uploads/2021/11/logo-social-1-2.png Hubank, director of clinical genomics (research) at The Royal Marsden NHS Foundation Trust, said: “We are delighted to announce this partnership with Guardant Health, establishing a state-of-the-art liquid biopsy testing facility. In a clinical diagnostic setting, it will provide many of our patients with more rapid access to bespoke diagnostic testing, leading to earlier, faster, and more accurate diagnosis, along with targeted treatment selection and monitoring.
“The opening of this service will also allow us to significantly increase our capacity for research using liquid biopsies. Bringing expanded capacity for genomic testing, the facility will help us identify more people with cancer for clinical trials based on targeted treatments, improving outcomes for patients across the UK and beyond.”
Jamie Foster, partner at Hill Dickinson, commented: “The accelerated adoption of innovative health tech in the NHS is proving transformational in the development of diagnostic tools, leading to improved patient outcomes. We were delighted to work with The Royal Marsden NHS Foundation Trust in setting up this partnership.”
The service will become operational at the end of 2022 – for clinical research and clinical care.
Date published: December 21, 2021